RNASeq of PDX and CDX tumours treated with ADC

Study ID Alternative Stable ID Type
EGAS00001004562 Other

Study Description

Enapotamab vedotin (EnaV), an antibody-drug conjugate (ADC) targeting AXL, effectively targets tumors that display insensitivity to immunotherapy and/or tumor-specific T cells in several melanoma and lung cancer models. Mechanistically, EnaV treatment induced an inflammatory response and immunogenic cell death in tumor cells, and promoted induction of a memory-like phenotype in cytotoxic T cells. Combining EnaV with tumor-specific T cells proved superior to any treatment alone in models of melanoma and lung cancer, and increased ICB benefit in models otherwise insensitive to anti-PD-1 treatment.

Study Datasets 1 dataset.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
RNAseq of tumours derived from NSCLC (n=3 PDX; n=1 CDX) and melanoma (n=1 CDX) xenograft models treated with ADC or controls (64 samples; 189 FASTQ files).
Illumina HiSeq 2500,Illumina NovaSeq 6000 64

Who archives the data?

There are no publications available